C Difficile

Gut Health: Initially used to combat recurring Clostridium difficile (C. diff) infections, FMT boasts a success rate of over 90 per cent. FMT has the potential to treat conditions such as inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), alcoholic liver disease, alcohol use disorder, Parkinson’s disease, autism spectrum disorder, metabolic syndrome and obesity. FMT is being used in several countries. Australia was the first to research and publish extensively in this field. FDA approved the treatment in the US for recurrent Clostridium difficile infection in 2013.

The portion of our nervous systems responsible for the "fight or flight" response can shape the severity of potentially deadly C. difficile infections, new research from the University of Virginia School ...

Use this handout to explain the basics of why infection prevention and control and antimicrobial stewardship are essential and how the 2 fields must have a unified approach to patient and staff safety

In this exclusive article, Devin Jopp, the CEO of APIC, discusses the upcoming day-long virtual conference entitled “APIC AI Summit: The Impact of AI on IPC.”

Clostridioides difficile is traditionally isolated from healthcare facilities' inpatients, but it is increasingly being identified in people who have not recently been hospitalized and is more and more found in community settings. Investigators from Perelman School of Medicine at University of Pennsylvania developed an mRNA-LNP vaccine with promising results in preventing and controlling C. difficile infection.

A study by Loveleen Tina Joshi, PhD raised concerns about bleach-resistant C difficile strains, and Curtis J. Donskey, MD, and his team answered.

CHARLOTTESVILLE, Va. (CBS19 NEWS) -- New research from the UVA School of Medicine has unveiled a potential way to fight C. difficile, which has been described as "a deadly plague"

Peptidoglycan synthesis is an essential driver of bacterial growth and division. The final steps of this crucial process involve the activity of SEDS family glycosyltransferases that polymerize glycan strands and class B penicillin-binding protein (bPBP) transpeptidases that cross-link them. While m …

Recurrent C. difficile infection is an urgent public health threat, for which the last resort and lifesaving treatment is a fecal microbiota transplant. However, the exact mechanisms that mediate a successful FMT are not well-understood. Here, we show ...

Clostridioides difficile is the leading cause of antibiotic-associated infections worldwide. Within the host, C. difficile can transition from a sessile to a motile state by secreting PPEP-1, which releases the cells from the intestinal epithelium by cleaving adhesion proteins. PPEP-1 …

Since the publication of the recent North American and European guidelines on management of Clostridioides difficile infection (CDI), new evidence describing the epidemiology, testing and treatment of CDI has emerged. Despite all advances in infection control and antibiotic stewardship, the incidenc …

A group of bacteria that can alter the gut's microbiome may be key to successful fecal transplants.

Clinical care of patients with rCDI now includes Food and Drug Administration-approved therapeutics to address microbiome restoration. Clinical trial evidence supports use of VOS following antibiotics and importance of microbiome restoration in rCDI.

Clostridioides difficile RT027 strains cause infections that vary in severity from asymptomatic to lethal, but the molecular basis for this variability is poorly understood. Through comparative analyses of RT027 clinical isolates, we determined that isolates that exhibit greater variability i …

Dear Doctors: I was sick for months with debilitating pain, extreme weight loss, fatigue and loss of appetite. I was diagnosed with C. diff related to an abdominal surgery. I’m

Clostridioides difficile is the leading cause of antibiotic-associated infections worldwide. Within the host, C. difficile can transition from a sessile to a motile state by secreting PPEP-1, which releases the cells from the intestinal epithelium by cleaving adhesion proteins. PPEP-1 …

Metronidazole monotherapy is associated with increased risk of recurrent CDI in SOT recipients. Therapeutic strategies aimed to reduce the risk of recurrence should be implemented in this setting.

We investigated the effects of Clostridioides difficile toxin B (TcdB), a major virulence factor in C. difficile infection (CDI), on human neutrophils. TcdB inhibits neutrophil migration via loss of polarity of F-actin polymerization in response to interleukin-8. TcdB facilitates CDI by allowing C. …

Early treatment for CDI had shortened hospital stay. However, it did not affect clinical outcomes in adult patients.

Tofacitinib was effective in the treatment of moderately severe ulcerative colitis in this real-world cohort in Lebanon. Further, the predictors associated with clinical and endoscopic remissions were found to be biologic-naïve status and reduction in CRP. Observed AEs were consistent with the known …

Outcomes were similar between patients treated with FDX and VAN for the treatment of CDI among those at high risk for rCDI, using our outlined criteria. Although we observed a trend toward lower rates of rCDI among immunocompromised patients, this finding was not significant. Further investigation i …

Ertapenem use for perioperative prophylaxis was associated with increased odds of SSI among patients undergoing colon surgery in our study population, though no differences in CDI or clinical CRE culture positivity were identified. Further study and replication of these findings are needed.

CP101 was superior to placebo in reducing recurrent CDI with a safety profile similar to placebo. https://clinicaltrials.gov/study/NCT03110133.

Seres Therapeutics (NASDAQ:MCRB) announced Tuesday that Nestlé Health Science, a unit of consumer care giant Nestle (OTCPK:NSRGY), has agreed to purchase its oral microbiome therapy Vowst for $175M. However, shares of the Cambridge, Massachusetts-based biotech fell ~21% in reaction. Developed by Seres (MCRB) and Nestlé Health Science, Vowst was app...

We investigated the effects of Clostridioides difficile toxin B (TcdB), a major virulence factor in C. difficile infection (CDI), on human neutrophils. TcdB inhibits neutrophil migration via loss of polarity of F-actin polymerization in response to interleukin-8. TcdB facilitates CDI by allowing C. …

Clostridioides difficile infection (CDI) is a leading cause of hospital-acquired infections in the United States, known for triggering severe disease by hyperactivation of the host response. In this study, we determine the impact of the sympathetic nervous system (SNS) on CDI disease severity. Mouse …

A large team of microbiologists, pathologists and infectious diseases specialists affiliated with several institutions in the U.S. has developed an mRNA vaccine that has thus far been found able to protect mice against intestinal Clostridioides difficile bacterial infections.

The risk of occurrence CDI for hospitalized patients using PPIs for SUP was higher than using H2RAs. It is recommended not to exceed 14 days of any gastric ASDs for SUP during hospitalization, especially for patients who have used high-risk antibiotics, been admitted to the ICU, or have immunodefici …

The online version contains supplementary material available at 10.1007/s13205-024-04102-7.